$300 Million Settlement in Benicar Litigation Over Drug Injury Claims

$300 Million Settlement in Benicar Litigation Over Drug Injury Claims

A $300 million settlement has been reached in the multidistrict Benicar litigation against Daiichi Sankyo Inc. and Forest Laboratories Inc. on claims that the top-selling blood pressure drug caused severe, and sometimes life-threatening, gastrointestinal injuries in users. [Read more…]

Congressional Bill HR 1215 Will Restrict Americans’ Rights to Obtain Justice in Medical Malpractice Cases

American Healthcare issues

Congress is about to vote on a bill that could restrict the rights of all Americans to obtain justice in our court system in cases of medical malpractice, including in cases involving negligent nursing homes and defective prescription drugs and medical devices. This bill would tip the scale against injured patients and their families in favor of the insurance industry and other large corporations. [Read more…]

Lexi Hazam Named to Plaintiffs Executive Committee in Nationwide Abilify Drug Injury Litigation

Lexi Hazam Named to Plaintiffs Executive Committee in Nationwide Abilify Drug Injury Litigation

On December 16, 2016, Chief Judge M. Casey Rodgers of the U.S. District Court for the Northern District of Florida issued an order appointing Lexi J. Hazam of Lieff Cabraser to the Plaintiffs’ Executive Committee in the multidistrict litigation previously consolidated in October 2016 over injuries and financial losses sustained by patients as a result of their use of the prescription drug Abilify. [Read more…]

Bristol-Myers Squibb Pays $19.5 Million Over Improper Abilify Drug Marketing

Abilify Gambling Addiction Injuries

Bristol-Myers Squibb has agreed to pay $19.5 million to settle claims of improper advertising relating to its top-selling drug Abilify. 42 states and Washington D.C. alleged that the company improperly advertised antipsychotic drug Abilify, first approved in 2002 by the FDA to treat schizophrenic in adults. However, Bristol-Myers Squibb thereafter began promoting Abilify for off-label uses not approved by the FDA. These off-label uses had not been established as safe or effective. [Read more…]

Abilify Gambling Lawsuits Consolidated in Florida Federal Court

Abilify Gambling Lawsuits Consolidated in Florida Federal Court

The Judicial Panel on Multidistrict Litigation has consolidated more than 20 lawsuits against Bristol-Myers Squibb Co. over claims of pathological gambling side effects in patients using the antipsychotic drug Abilify in federal court in Florida. The serious impulse-control problems described in the complaints reportedly stop when the medicine is discontinued. 22 actions pending in 12 districts will be centralized under Chief District Judge M. Casey Rodgers. [Read more…]

Study Finds Majority of Parents Give Their Children Wrong Dose of Liquid Medication

Study Finds Majority of Parents Give Their Children Wrong Dose of Liquid Medication

A study by various pediatric clinics located in New York, Atlanta, and California has discovered that the majority of parents unknowingly provide their children with the wrong dosage of liquid medication. This is occurring in part because despite pediatric medicines including a measuring tool with related instructions, often the units on the label – milliliters, mL, teaspoon, tsp., tablespoon – differ from what’s on the tools themselves. [Read more…]

Upcoming FDA Public Hearing on Off-Label Drug and Device Use

Upcoming FDA Public Hearing on Off-Label Drug and Device Use

The U.S. Food and Drug Administration (FDA) has announced a public hearing forum to take place on November 9-10, 2016 with regard to the enforcement of rules relating to off-label drug and medical product use in the public health industry. The registration deadline to present at the hearing is October 19, 2016, and the deadline for written commentary after the hearing is January 9, 2017. [Read more…]

Levaquin and Cipro, Secret Killers via Aneurysm, Aortic Dissection

female doctor examining a teenage girl in her office

Hundreds of Americans with Minor Infections Are Dying Every Year from Aneurysms That May Have Been Caused by the Super-Antibiotics they Should Never Have Been Prescribed

A class of strong antibiotic drugs including Levaquin and Cipro prescribed widely to treat common bacterial infections like urinary tract infections, bronchitis, and sinusitis have been linked to significantly increased risks of potentially life-threatening aortic aneurysms and aortic dissections. [Read more…]

Lieff Cabraser Announces Filing of Personal Injury Lawsuit Against Bristol-Myers Squibb and Otsuka Pharmaceutical for Damages Caused by Abilify Prescription Drug

high contrast image of casino roulette

Gambling addiction lawsuit alleges claims including Strict Liability, Negligent Misrepresentation, and Fraudulent Concealment, and seeks damages for neuropsychiatric, mental, physical, and economic damages, as well as punitive damages

Lexi J. Hazam of the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein, LLP, announces that Rikki Carlson of Fall River, Massachusetts, has filed a personal injury lawsuit against Bristol-Myers Squibb Company, Otsuka Pharmaceutical Co., Ltd., and Otsuka America Pharmaceutical, Inc. (“Defendants”) for damages suffered as a direct and proximate result of Defendants’ wrongful conduct in connection with the development, design, testing, labeling, packaging, promoting, advertising, marketing, distribution, and selling of the blockbuster prescription drug Abilify.

[Read more…]

Risperdal Injury Trial Leads to $70 Million Verdict Against Johnson & Johnson in Pennsylvania

Risperdal gynecomastia injuries and lawsuits

Law360 reports (subscription) that Johnson & Johnson received a $70 million verdict on a Philadelphia Risperdal injury case where side effectsd of the widely-prescribed antipsychotic drug caused an adolescent boy to grow prominent breasts. This verdict is significantly higher than other recent Pennsylvania Risperdal injury judgments against J&T over allegations that the drug caused breast growth. [Read more…]

Pro Publica: Why Drug Testing’s Omission of Pregnant Women May Have Led to Zofran Birth Defect Injuries

California Parents File Zofran Lawsuit Against GlaxoSmithKline

Pro Publica has published a lengthy article exploring how the medical establishment’s long-standing approach to “protecting” fetuses by restricting testing on pregnant women has resulted in a critical shortfall of knowledge. While the intention was mostly good — to protect women and babies from the kind of severe birth defects and other harm caused by thalidomide and other drugs in the 1960s and ‘70s (but also to protect pharmaceutical companies from legal liability for those injuries) — the result is less certain. By excluding women — and pregnant women in particular — from clinical trials, doctors have been forced into prescribing untried medications “off-label” to pregnant women, with results that can lead to serious negative health consequences for mothers, and birth defects for babies. [Read more…]

FDA Warning: Antipsychotic Drug Abilify Linked to Severe Compulsive Behavior and Addiction

FDA Warning: Antipsychotic Drug Abilify Linked to Severe Compulsive Behavior and Addiction

The Food and Drug Administration (FDA) has issued a formal warning that the use of the antipsychotic drug aripiprazole (Abilify, Abilify Maintena, Aristada, and also used in generic versions of the drug) has been linked to compulsive urges, which can lead to uncontrollable gambling, among other addictions. These rare but serious impulse-control problems reportedly stop when the medicine is discontinued or markedly reduced in dosage. [Read more…]

Xarelto Litigation Scheduling Order Sets Injury Cases in Motion

Xarelto Litigation Scheduling Order Sets Injury Cases in Motion

On April 21, 2016, Judge Eldon E. Fallon, the federal judge supervising and overseeing the centralized litigation against Janssen, Johnson & Johnson and Bayer over Xarelto, issued an order scheduling the depositions of plaintiffs and defense witnesses. The court is overseeing the discovery necessary to develop several “bellwether” trials in order to evaluate the strength and weaknesses of the cases brought against the pharmaceutical giants and to determine the values of certain harms and injuries. [Read more…]

Mark Chalos Comments on First Round of Patient Settlement Recovery in Meningitis Outbreak Cases

Mark Chalos Comments on First Round of Patient Settlement Recovery in Meningitis Outbreak Cases

In 2012, more than 14,000 patients across the U.S. were injected with a contaminated medication that caused an outbreak of potentially deadly fungal meningitis. The New England Compounding Center (“NECC”) in Framingham, Massachusetts, manufactured and sold the drug – an epidural steroid treatment designed to relieve back pain. The contaminated steroid was sold to patients at a number of pain clinics. Nearly 800 patients developed fungal meningitis, and more than 70 patients died. [Read more…]

Products Containing Talcum Powder Linked to Ovarian Cancer

Products Containing Talcum Powder Linked to Ovarian Cancer

As revealed in a recent civil lawsuit, certain household and body products containing talcum powder have been linked to ovarian cancer in women. A Missouri jury reached a verdict of $72 million against Johnson & Johnson in a case claiming the health care company’s baby powder product containing talcum caused the decedent plaintiff’s ovarian cancer. This marks the first suit among the more than 1,000 talc exposure cases filed nationwide to result in a jury verdict for the plaintiff. [Read more…]

Xarelto Bleed Injury Timeline 2016, Lawsuit Updates, and Patient Information

Xarelto Event Timeline

Xarelto Release in 2011 Leads to Thousands of Serious Injuries by 2014, Consolidated Lawsuits Through 2016-2017

Xarelto Multidistrict Litigation – Case Update

The Xarelto multidistrict bellwether litigation is moving forward in the U.S. District Court in the Eastern District of Louisiana. The Court asked the parties in late December 2015 to select pool cases, which selection was completed January 11, 2016. The Court also requested that the chosen cases reflect multiple Xarelto injury categories, including gastrointestinal bleed and gi bleeding, brain bleeding events, hemorrhages, and hemorrhagic strokes. The Court is expected to select additional cases for inclusion originating in multiple states. The first trials are set for early February 2017 in Louisiana, with subsequent trials to occur in Mississippi and Texas in April and May 2017.

[Read more…]

Xarelto Bleed Injury Timeline Updates and Patient Information

Xarelto bleeding injury lawsuits timeline

Drug’s Release in 2011 Leads to Thousands of Serious Injuries by 2014, Consolidated Lawsuits Through 2015

Xarelto was released in July 2011 to prevent blood clots in patients undergoing knee and hip surgeries, and its use was then expanded to include patients with irregular heartbeats or facing likely lung and leg blood clots. It was also used to prevent clots in some people with atrial fibrillation. The drug is taken as a pill with the chemical name rivaroxaban. The new Xarelto patient information injury and lawsuit timeline shown below tracks Xarelto from its release to thousands of patient injury reports less than two years later, to thousands of Xarelto death and uncontrolled bleeding injury lawsuits slated for bellwether treatment in 2016 and 2017. [Read more…]